Literature DB >> 14734157

Ovarian cancer in the elderly.

Sandro Pignata1, Jan B Vermorken.   

Abstract

In Europe 58% of all female cancers occur in women older than 65 years. The incidence of ovarian cancer rises steadily with advancing age during adulthood and peaks in the 7th-8th decades of life. Age-specific analysis reveals that the incidence of and mortality rate from ovarian cancer are continuously increasing in the elderly population. Although more advanced stage at diagnosis seems to be one of the determinants of the worst prognosis of the elderly population, the majority of clinicians seem to be unprepared to treat elderly patients, and a great number of patients are under-treated for the fear of unacceptable side-effects, thus limiting their possibility of survival. Guidelines are clearly needed; including advice on whether to treat at all and whether standard surgery or chemotherapy is feasible in elderly patients with ovarian cancer. Research on MEDLINE using as keywords 'elderly and ovarian cancer' reveals few papers, which reported data in this field. Nonetheless, in this report we will focus on four basic aspects of ovarian cancer in the elderly: the most important factors affecting prognosis, the safety of surgical treatment in aged patients, optimal first and second line chemotherapy, and the use of supportive treatments to improve quality of life.

Entities:  

Mesh:

Year:  2004        PMID: 14734157     DOI: 10.1016/s1040-8428(03)00100-8

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  9 in total

Review 1.  Imaging of female pelvic malignancies regarding MRI, CT, and PET/CT: Part 2.

Authors:  Celine D Alt; Kerstin A Brocker; Michael Eichbaum; Christof Sohn; Florian U Arnegger; Hans-Ulrich Kauczor; Peter Hallscheidt
Journal:  Strahlenther Onkol       Date:  2011-10-28       Impact factor: 3.621

2.  Feasibility and safety of extensive upper abdominal surgery in elderly patients with advanced epithelial ovarian cancer.

Authors:  Myong Cheol Lim; Sokbom Kang; Yong Jung Song; Sae Hyun Park; Sang-Yoon Park
Journal:  J Korean Med Sci       Date:  2010-06-17       Impact factor: 2.153

3.  Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients.

Authors:  Brent S Pedersen; Panagiotis A Konstantinopoulos; Monique A Spillman; Subhajyoti De
Journal:  Genes Chromosomes Cancer       Date:  2013-05-28       Impact factor: 5.006

4.  Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT.

Authors:  Kazuhiro Kitajima; Koji Murakami; Erena Yamasaki; Yasushi Kaji; Ichio Fukasawa; Noriyuki Inaba; Kazuro Sugimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

Review 5.  Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI.

Authors:  Rosemarie Forstner
Journal:  Eur Radiol       Date:  2007-08-14       Impact factor: 5.315

6.  Considerations regarding the administration of systemic therapy for elderly patients with ovarian cancer.

Authors:  William P Tew
Journal:  Curr Treat Options Oncol       Date:  2013-03

7.  A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis.

Authors:  Sven Mahner; Gülten Oskay-Özcelik; Elke Heidrich-Lorsbach; Stefan Fuxius; Harald Sommer; Peter Klare; Antje Belau; Birgit Ruhmland; Thomas Heuser; Heinz Kölbl; Susanne Markmann; Jalid Sehouli
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-15       Impact factor: 4.553

8.  Age is associated with prognosis in serous ovarian carcinoma.

Authors:  Fei Deng; Xia Xu; Mengmeng Lv; Binhui Ren; Yan Wang; Wenwen Guo; Jifeng Feng; Xiaoxiang Chen
Journal:  J Ovarian Res       Date:  2017-06-12       Impact factor: 4.234

9.  Development and Validation of Prognostic Nomogram for Primary Peritoneal Serous Carcinoma Compared With FIGO Staging System: A Population-Based Study.

Authors:  Ming Chen; Zhenzhen Wen; Zhengwei Qi; Min Gao
Journal:  Front Oncol       Date:  2021-08-19       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.